Prevelence of Kidney Related Disease Drives Global Renal Biomarker Market

Growing prevalence of various kidney-related diseases among individuals globally is the major factor driving the growth of the global renal biomarkers market. Chronic kidney disease (CKD) is a disorder that causes reduced kidney function over some time. It may develop over many years and lead to end-stage kidney disease (ESRD).

Chronic kidney disease (CKD) is a disorder that causes reduced kidney function over some time. It may develop over many years and lead to end-stage kidney disease (ESRD).

Kidney-related diseases has become a massive public health issue that endures rising. As per the data published by the Global Burden of Disease Study, kidney disease was the 12th-most common cause of death, estimating for 1.1 million deaths globally in 2015. CKD mortality increased by 31.7% over the past decade, making it one of the fastest rising major causes of death, along with dementia and diabetes.

The Global Renal Biomarker Market accounted for $1.084 billion in 2020 and is estimated to be $2.23 billion by 2030 and is anticipated to register a CAGR of 7.50%. A biomarker is a measurable pointer of a specific biological state and it gives a reflection of the stage of, or the presence of, a disease. Renal biomarkers can be used clinically to screen, monitor or diagnose certain kidney-related diseases. They are also used to guide molecularly targeted therapy or to assess therapeutic response.

Key Highlights:

  • In February 2019, Spark Therapeutics Inc. and Roche declared a definitive merger agreement, which enables Roche to fully acquire Spark Therapeutics at a price of $114.50 per share, in an all-cash transaction.

To know the upcoming trends and insights prevalent in this market, click the link

Key Market Insights from the report:

Growing prevalence of various kidney-related diseases among individuals globally is the major factor driving the growth of the global renal biomarkers market.

The global renal biomarkers market is segmented based on biomarker type, diagnostic technique, end-user, and region.

  • Based on biomarker type, the global renal biomarkers market is segmented into functional biomarker and up-regulated protein. Functional biomarker segment is further divided into serum creatinine, serum cystatin C, and urine albumin. Up-regulated protein segment is further divided into neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1, and INTERLEUKIN-18.
  • Based on diagnostic technique, the target market is segmented into enzyme-linked immunosorbent assay, particle-enhanced turbidimetric immunoassay (PETIA), colorimetric assay, chemiluminescent enzyme immunoassay (CLIA), and others.
  • Based on end-user, the global market is classified into a hospital, diagnostic laboratory, and other end users.
  • Based on the region the global renal biomarkers market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are estimated to remain the dominant markets for renal biomarkers owing to robust economic growth, high expenditure on health care, and high awareness and acceptance of novel diagnostic methods in the regions.

Competitive Landscape:

The key players operating the global renal biomarkers market involves Abbott Laboratories, BioPorto Diagnostics A/S, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Pacific Biomarkers, BioMérieux, Beckman Coulter (Danaher Corporation), Randox Laboratories Ltd., and Siemens Healthineers

Get report

Santosh M.

I am digital marketer in prophecy market insights.
https://www.prophecymarketinsights.com/